Plain-English translation of NCT05285891 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether people with early relapsing multiple sclerosis can safely stop taking — a medication that calms the immune system — after two years, or whether they need to keep taking it long-term. Everyone starts by taking the medication for 24 months. Then, some people will continue getting the medication every six months, while others will switch to a placebo (a fake treatment) to see if the disease stays under control without it.
Doctors don't yet know whether patients with early relapsing MS can eventually stop this medication safely, or if they need to stay on it forever. This study will help answer that important question and could change how people are treated long-term.
You likely qualify if…
You likely don't qualify if…
You will start by receiving the medication through intravenous infusions over your first two years in the study. During this time, you'll have regular visits for physical exams, neurological check-ups, blood tests, and MRI brain scans to monitor your MS. At the two-year mark, you'll be randomly assigned to either continue getting the medication every six months or switch to a placebo infusion for another two years. The entire study lasts four years, with frequent visits and testing throughout to carefully track whether your MS stays stable.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States